Published in Dig Dis Sci on September 08, 2011
Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol (2013) 1.22
Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis--a longitudinal study. PLoS One (2013) 1.04
Non-alcoholic fatty liver disease: what the clinician needs to know. World J Gastroenterol (2014) 1.02
Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation. Int J Mol Sci (2014) 1.00
Mediterranean diet and health: food effects on gut microbiota and disease control. Int J Mol Sci (2014) 0.98
Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease. World J Gastroenterol (2014) 0.96
Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development. World J Gastroenterol (2014) 0.94
Metabolic endotoxemia with obesity: Is it real and is it relevant? Biochimie (2015) 0.93
The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol (2016) 0.93
How gut microbes talk to organs: The role of endocrine and nervous routes. Mol Metab (2016) 0.91
Gut-liver axis, nutrition, and non-alcoholic fatty liver disease. Clin Biochem (2015) 0.91
Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease. World J Gastroenterol (2014) 0.90
Probiotics in prevention and treatment of obesity: a critical view. Nutr Metab (Lond) (2016) 0.89
The role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liver disease. Nutrients (2014) 0.88
Probiotics and Nonalcoholic Fatty liver Disease. Middle East J Dig Dis (2013) 0.88
Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol (2014) 0.87
Modulation of the gut microbiota by nutrients with prebiotic and probiotic properties. Adv Nutr (2014) 0.86
Gut microbiota and liver diseases. World J Gastroenterol (2015) 0.86
Effect of fructooligosaccharides fraction from Psacalium decompositum on inflammation and dyslipidemia in rats with fructose-induced obesity. Nutrients (2014) 0.85
Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options. Drug Des Devel Ther (2015) 0.84
Gut microbiota in alcoholic liver disease: pathogenetic role and therapeutic perspectives. World J Gastroenterol (2014) 0.83
SYNbiotics Easing Renal failure by improving Gut microbiologY (SYNERGY): a protocol of placebo-controlled randomised cross-over trial. BMC Nephrol (2014) 0.81
Gastrointestinal microbiome modulator improves glucose tolerance in overweight and obese subjects: A randomized controlled pilot trial. J Diabetes Complications (2015) 0.80
Mechanisms Linking the Gut Microbiome and Glucose Metabolism. J Clin Endocrinol Metab (2016) 0.80
Gut Microbiota and Lifestyle Interventions in NAFLD. Int J Mol Sci (2016) 0.79
Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease. World J Hepatol (2015) 0.78
The Metabolic Role of Gut Microbiota in the Development of Nonalcoholic Fatty Liver Disease and Cardiovascular Disease. Int J Mol Sci (2016) 0.78
Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota. Am J Physiol Gastrointest Liver Physiol (2016) 0.78
Diet, Microbiota, Obesity, and NAFLD: A Dangerous Quartet. Int J Mol Sci (2016) 0.78
Do symbiotic and Vitamin E supplementation have favorite effects in nonalcoholic fatty liver disease? A randomized, double-blind, placebo-controlled trial. J Res Med Sci (2016) 0.77
Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanism and Application of Metabolomics. Int J Mol Sci (2016) 0.77
Gut Microbiota: Association with NAFLD and Metabolic Disturbances. Biomed Res Int (2015) 0.77
The Effect of Symbiotic Supplementation on Liver Enzymes, C-reactive Protein and Ultrasound Findings in Patients with Non-alcoholic Fatty Liver Disease: A Clinical Trial. Int J Prev Med (2016) 0.77
A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD. Gastroenterol Res Pract (2016) 0.77
Significance of Microbiota in Obesity and Metabolic Diseases and the Modulatory Potential by Medicinal Plant and Food Ingredients. Front Pharmacol (2017) 0.76
Gut Microbiota of Nonalcoholic Fatty Liver Disease. Dig Dis Sci (2016) 0.76
Treatment of nonalcoholic steatohepatitis in adults: present and future. Gastroenterol Res Pract (2015) 0.76
Relevant Aspects of Nutritional and Dietary Interventions in Non-Alcoholic Fatty Liver Disease. Int J Mol Sci (2015) 0.76
Gut microbiota: Changes in gut microbes and host metabolism: squaring the circle? Nat Rev Gastroenterol Hepatol (2016) 0.75
Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol. BMC Gastroenterol (2015) 0.75
More on current evidences on probiotics as a novel treatment for non-alcoholic Fatty liver disease. Hepat Mon (2013) 0.75
Is there a role for probiotics in liver disease? ScientificWorldJournal (2014) 0.75
Can probiotics modulate human disease by impacting intestinal barrier function? Br J Nutr (2017) 0.75
Effects of symbiotic and vitamin E supplementation on blood pressure, nitric oxide and inflammatory factors in non-alcoholic fatty liver disease. EXCLI J (2017) 0.75
Beneficial Effect of Synbiotic Supplementation on Hepatic Steatosis and Anthropometric Parameters, But Not on Gut Permeability in a Population with Nonalcoholic Steatohepatitis. Nutrients (2016) 0.75
Choline and Fructooligosaccharide: Non-alcoholic Fatty Liver Disease, Cardiac Fat Deposition, and Oxidative Stress Markers. Nutr Metab Insights (2015) 0.75
The role of the gastrointestinal tract and microbiota on uremic toxins and chronic kidney disease development. Clin Exp Nephrol (2016) 0.75
Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (2005) 29.57
Compendium of physical activities: classification of energy costs of human physical activities. Med Sci Sports Exerc (1993) 19.40
Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol (1999) 14.07
World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA (1997) 9.54
Non-alcoholic steatohepatitis: another disease of affluence. Lancet (1999) 4.28
Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology (2004) 4.06
Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology (2003) 4.03
Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci U S A (1997) 3.79
Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology (2002) 3.29
Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin. Gastroenterology (1995) 3.26
Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab (1999) 3.00
A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology (2010) 2.67
Disrupted signaling and inhibited regeneration in obese mice with fatty livers: implications for nonalcoholic fatty liver disease pathophysiology. Hepatology (2001) 2.14
Probiotics in human medicine. Gut (1991) 2.06
Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol (2005) 1.93
Effects of the in vitro fermentation of oligofructose and inulin by bacteria growing in the human large intestine. J Appl Bacteriol (1993) 1.87
The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol (2010) 1.79
Molecular mechanisms involved in NAFLD progression. J Mol Med (Berl) (2009) 1.50
Increased liver echogenicity at ultrasound examination reflects degree of steatosis but not of fibrosis in asymptomatic patients with mild/moderate abnormalities of liver transaminases. Dig Liver Dis (2002) 1.39
Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics. J Hepatol (2003) 1.31
Rapidly available glucose in foods: an in vitro measurement that reflects the glycemic response. Am J Clin Nutr (1999) 1.22
C-reactive protein, inflammation, and coronary risk. Cardiol Clin (2003) 1.22
Kupffer cell-derived prostaglandin E(2) is involved in alcohol-induced fat accumulation in rat liver. Am J Physiol Gastrointest Liver Physiol (2000) 1.20
Obesity and female gender increase breath ethanol concentration: potential implications for the pathogenesis of nonalcoholic steatohepatitis. Am J Gastroenterol (2001) 1.12
L-carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis--a randomized and controlled clinical trial. Am J Gastroenterol (2010) 1.10
Bifidobacterium longum with fructo-oligosaccharide (FOS) treatment in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. Dig Dis Sci (2007) 1.01
The role of immunity in elderly cancer. Crit Rev Oncol Hematol (2009) 0.98
Carbohydrate fermentation decreases hepatic glucose output in healthy subjects. Metabolism (1993) 0.97
Effects of oligofructose on glucose and lipid metabolism in patients with nonalcoholic steatohepatitis: results of a pilot study. Eur J Clin Nutr (2005) 0.97
Chitotriosidase gene expression in Kupffer cells from patients with non-alcoholic fatty liver disease. Gut (2006) 0.97
Chronic consumption of short-chain fructooligosaccharides does not affect basal hepatic glucose production or insulin resistance in type 2 diabetics. J Nutr (2000) 0.97
Dietary oligofructose lessens hepatic steatosis, but does not prevent hypertriglyceridemia in obese zucker rats. J Nutr (2000) 0.94
Prognostic indicators of hepatic injury following jejunoileal bypass performed for refractory obesity: a prospective study. Hepatology (1981) 0.92
Potential role of chitotriosidase gene in nonalcoholic fatty liver disease evolution. Am J Gastroenterol (2006) 0.92
Bifidobacterium combined with fructo-oligosaccharide versus lactulose in the treatment of patients with hepatic encephalopathy. Eur J Gastroenterol Hepatol (2010) 0.90
Bright liver, body composition and insulin resistance changes with nutritional intervention: a follow-up study. Liver Int (2008) 0.85
Probiotics and prebiotics: can regulating the activities of intestinal bacteria benefit health? West J Med (1999) 0.83
Treatment of non-alcoholic fatty liver disease. J Gastroenterol Hepatol (2002) 0.81
Saccharomyces: is it a probiotic or a pathogen and what is the significance of an elevated anti-S. cerevisiae antibody? J Clin Gastroenterol (2003) 0.78
Anti-inflammatory strategies in alcoholic steatohepatitis. J Gastroenterol Hepatol (2007) 0.77
The effects of undigestible fructooligosaccharides on intestinal microflora and various physiological functions on human health. Adv Exp Med Biol (1990) 0.77
Adipocytokine polymorphisms and nonalcoholic fatty liver disease. J Gastroenterol Hepatol (2009) 0.75
Worldwide epidemiology of liver hydatidosis including the Mediterranean area. World J Gastroenterol (2012) 2.21
Normal-weight obese syndrome: early inflammation? Am J Clin Nutr (2007) 2.10
Hepatic echinococcosis: clinical and therapeutic aspects. World J Gastroenterol (2012) 2.10
Serum markers of hepatocellular carcinoma. Dig Dis Sci (2010) 1.76
Thin glomerular basement membrane disease: clinical significance of a morphological diagnosis--a collaborative study of the Italian Renal Immunopathology Group. Nephrol Dial Transplant (2004) 1.46
Supercentenarians: the oldest people in the world. Indian J Med Res (2010) 1.44
Metal fume fever. Lancet (2013) 1.43
Hepatocellualar carcinoma serum markers. Semin Oncol (2012) 1.39
Inherited apolipoprotein A-V deficiency in severe hypertriglyceridemia. Arterioscler Thromb Vasc Biol (2004) 1.31
Protocatechuic acid is the major human metabolite of cyanidin-glucosides. J Nutr (2007) 1.27
Diversity in metabolite production by Fusarium langsethiae, Fusarium poae, and Fusarium sporotrichioides. Int J Food Microbiol (2004) 1.17
Effects of vitamin C on health: a review of evidence. Front Biosci (Landmark Ed) (2013) 1.14
Major postoperative complications and survival for colon cancer elderly patients. BMC Surg (2012) 1.12
L-carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis--a randomized and controlled clinical trial. Am J Gastroenterol (2010) 1.10
Overexpression of human heme oxygenase-1 attenuates endothelial cell sloughing in experimental diabetes. Am J Physiol Heart Circ Physiol (2004) 1.09
Serum markers of intrahepatic cholangiocarcinoma. Dis Markers (2013) 1.07
Cyanidin-3-O-β-glucoside and protocatechuic acid exert insulin-like effects by upregulating PPARγ activity in human omental adipocytes. Diabetes (2011) 1.05
Silibinin modulates lipid homeostasis and inhibits nuclear factor kappa B activation in experimental nonalcoholic steatohepatitis. Transl Res (2012) 1.04
Nuclear translocation of heme oxygenase-1 confers resistance to imatinib in chronic myeloid leukemia cells. Curr Pharm Des (2013) 1.04
Elevated incidence of hypospadias in two sicilian towns where exposure to industrial and agricultural pollutants is high. Reprod Toxicol (2003) 1.04
Systemic therapies in hepatocellular carcinoma: present and future. Future Oncol (2013) 1.03
Potential therapeutic effects of natural heme oxygenase-1 inducers in cardiovascular diseases. Antioxid Redox Signal (2012) 1.02
Potential role of probiotics on colorectal cancer prevention. BMC Surg (2012) 1.01
Laparoscopic-assisted versus open surgery for colorectal cancer: short- and long-term outcomes comparison. J Laparoendosc Adv Surg Tech A (2012) 1.01
Neuroprotective effect of silibinin in diabetic mice. Neurosci Lett (2011) 1.00
Hsp60 and heme oxygenase-1 (Hsp32) in acute myocardial infarction. Transl Res (2011) 1.00
Role of dietary and endogenous antioxidants in diabetes. Crit Rev Food Sci Nutr (2014) 1.00
Silibinin improves hepatic and myocardial injury in mice with nonalcoholic steatohepatitis. Dig Liver Dis (2011) 0.99
A retrospective study on acute health effects due to volcanic ash exposure during the eruption of Mount Etna (Sicily) in 2002. Multidiscip Respir Med (2013) 0.99
Red orange: experimental models and epidemiological evidence of its benefits on human health. Oxid Med Cell Longev (2013) 0.98
L-carnitine supplementation improves hematological pattern in patients affected by HCV treated with Peg interferon-α 2b plus ribavirin. World J Gastroenterol (2011) 0.98
Toxic hepatitis in occupational exposure to solvents. World J Gastroenterol (2012) 0.98
Mediterranean diet and cancer: epidemiological evidence and mechanism of selected aspects. BMC Surg (2013) 0.97
Clinical and genetic characterization of Chanarin-Dorfman syndrome. Biochem Biophys Res Commun (2008) 0.97
Mediterranean diet and cardiovascular risk factors: a systematic review. Crit Rev Food Sci Nutr (2014) 0.97
Efficacy of adipose tissue-mesenchymal stem cell transplantation in rats with acetaminophen liver injury. Stem Cell Res (2013) 0.97
The effects of dietary flavonoids on the regulation of redox inflammatory networks. Front Biosci (Landmark Ed) (2012) 0.97
Effect of silibinin on endothelial dysfunction and ADMA levels in obese diabetic mice. Cardiovasc Diabetol (2011) 0.96
Nutrition knowledge and other determinants of food intake and lifestyle habits in children and young adolescents living in a rural area of Sicily, South Italy. Public Health Nutr (2012) 0.96
Prevalence of Ureaplasma urealyticum and Mycoplasma hominis infection in unselected infertile men. J Chemother (2012) 0.95
Congenital talipes equinovarus: an epidemiological study in Sicily. Acta Orthop (2012) 0.95
Oxidative stress in normal-weight obese syndrome. Obesity (Silver Spring) (2010) 0.95
Aging exacerbates negative remodeling and impairs endothelial regeneration after balloon injury. Am J Physiol Heart Circ Physiol (2004) 0.94
Laparoscopic vs. open approach for colorectal cancer: evolution over time of minimal invasive surgery. BMC Surg (2013) 0.94
New markers of neonatal neurology. J Matern Fetal Neonatal Med (2009) 0.94
L-Carnitine treatment reduces severity of physical and mental fatigue and increases cognitive functions in centenarians: a randomized and controlled clinical trial. Am J Clin Nutr (2007) 0.94
Novel inhibitors of nitric oxide synthase with antioxidant properties. Eur J Med Chem (2012) 0.93
Health related quality of life in colorectal cancer patients: state of the art. BMC Surg (2013) 0.93
Natural heme oxygenase-1 inducers in hepatobiliary function. World J Gastroenterol (2008) 0.92
Acetyl-L-carnitine treatment in minimal hepatic encephalopathy. Dig Dis Sci (2008) 0.92
Cyanidin-3-O-beta-glucopyranoside protects myocardium and erythrocytes from oxygen radical-mediated damages. Free Radic Res (2003) 0.91
Beneficial effects of rutin and L-arginine coadministration in a rat model of liver ischemia-reperfusion injury. Am J Physiol Gastrointest Liver Physiol (2008) 0.90
Bifidobacterium combined with fructo-oligosaccharide versus lactulose in the treatment of patients with hepatic encephalopathy. Eur J Gastroenterol Hepatol (2010) 0.90
Markers of bile duct tumors. World J Gastrointest Oncol (2011) 0.90
Age is an important predictor of kidney transplantation outcome. Nephrol Dial Transplant (2011) 0.90
The physiopathology of lipoprotein (a). Front Biosci (Schol Ed) (2010) 0.89
Propofol attenuates peroxynitrite-mediated DNA damage and apoptosis in cultured astrocytes: an alternative protective mechanism. Anesthesiology (2004) 0.89
Lipoprotein(a) serum levels in diabetic patients with retinopathy. Biomed Res Int (2013) 0.89
A review of transcranial magnetic stimulation in vascular dementia. Dement Geriatr Cogn Disord (2011) 0.89
The role of nutrition in the development of esophageal cancer: what do we know? Front Biosci (Elite Ed) (2012) 0.89
Elevated serum levels of Chromogranin A in hepatocellular carcinoma. BMC Surg (2012) 0.89
L-Carnitine supplementation reduces oxidized LDL cholesterol in patients with diabetes. Am J Clin Nutr (2008) 0.89
Transcranial magnetic stimulation in Alzheimer's disease: a neurophysiological marker of cortical hyperexcitability. J Neural Transm (Vienna) (2011) 0.89
Neurotoxicity of acrylamide in exposed workers. Int J Environ Res Public Health (2013) 0.89
Effects of blood orange juice intake on antioxidant bioavailability and on different markers related to oxidative stress. J Agric Food Chem (2005) 0.88
Human chitotriosidase polymorphism is associated with human longevity in Mediterranean nonagenarians and centenarians. J Hum Genet (2009) 0.88
Nitric oxide-related toxicity in cultured astrocytes: effect of Bacopa monniera. Life Sci (2003) 0.88
Rare benign tumors of the liver: still rare? J Gastrointest Cancer (2014) 0.88
Moro orange juice prevents fatty liver in mice. World J Gastroenterol (2012) 0.88
The supplementation of acetyl-L-carnitine decreases fatigue and increases quality of life in patients with hepatitis C treated with pegylated interferon-α 2b plus ribavirin. J Interferon Cytokine Res (2011) 0.88